Linvoseltamab (bcmaxcd3) initial pivotal phase 2 data show clinically meaningful responses in patients with heavily pre-treated multiple myeloma

As presented at ash, recommended 200 mg dose of linvoseltamab demonstrated a 64% response rate, with 45% of responders achieving a very good partial response or better; responses may further improve with longer follow-up trial enrolled patients with particularly high disease burden, with 37% having bone marrow plasma cells ≥50% and the median soluble bcma being 0.43 mg/l data represent initial efficacy results from first 58 patients in ongoing phase 2 trial, which is now fully enrolled at the recommended dose tarrytown, n.y. , dec. 12, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced positive initial data from a pivotal phase 2 expansion cohort evaluating investigational linvoseltamab (formerly regn5458) at the 200 mg dose recommended for further development in patients with heavily pre-treated, relapsed/refractory (r/r) multiple myeloma.
REGN Ratings Summary
REGN Quant Ranking